Gen Alpha (children 14 and younger) led the rise of GLP-1 utilization from 2023 to 2024, with an 85% growth rate in that period. But what is behind the sharp increase? 3 factors at play There are several factors behind increased GLP-1 utilization in children. 1. The first is the obesity epidemic. About one-third of […]
What’s driving the rise of GLP-1 utilization in children? Read More »
Some users of GLP-1 weight-loss drugs have been reporting strange changes in food preferences, such as a new dislike for meats or fried foods, and scientists are beginning to figure out why
Why Ozempic and Wegovy Might Change Your Favorite Food Read More »
As broader approval for GLP-1 weight loss drugs spurs higher demand, it’s also causing employer drug spending to spike.
GLP-1s can help employers lower medical costs in 2 years, new study finds Read More »
All it takes to change a pest to a partner is a signature on a dotted line. Danish pharmaceutical giant Novo Nordisk, the maker of leading weight-loss drug Wegovy, is signing a deal with online telehealth storefronts that ate a chunk of its business selling cheap knockoffs during shortages last year. Slimmed-Down Offering Novo Nordisk’s
Wegovy-Maker Novo Teams with Online Pharmacies as Lilly Rivalry Heats Up Read More »
GLP-1s can help employers lower medical costs in 2 years, new study finds CNBC Aon Unveils First Workforce-Focused Analysis on GLP-1s: Medications and Holistic Support Can Transform Workforce Health and Bend the Cost Curve Yahoo Finance GLP-1s are evolving — How benefit managers can prepare Employee Benefit News Wondr Health Launches GLP-1 Support For All Benefit Plans HIT Consultant
GLP-1s can help employers lower medical costs in 2 years, new study finds – CNBC Read More »
How GLP-1 drugs like Mounjaro and Ozempic are redefining the debate about size, weight loss and privilege
How Ozempic and Other GLP-1 Drugs Are Eating Away at Body Positivity Read More »
PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ — Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on…
Click in for more news from The Hill {beacon} Health Care The Big Story Novo Nordisk partners with telehealth firms to sell Wegovy Novo Nordisk is working with telehealth companies to sell a cheaper version of its injectable weight-loss drug Wegovy, launching the partnership after these companies became unable to sell compounded, unapproved versions
Telehealth patients get access to more weight-loss drugs Read More »
Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform. The post Novo Nordisk Forms GLP-1 Partnership with Hims & Hers appeared first on MedCity News.
Novo Nordisk Forms GLP-1 Partnership with Hims & Hers Read More »
(MedPage Today) — LAS VEGAS — A history of treatment with a GLP-1 receptor agonist had limited impact on sperm abnormalities in men with obesity, a retrospective cohort study suggested. Men who had at least one prescription for semaglutide…
Little Evidence That GLP-1 Agonists Affect Fertility in Men Read More »